| abstract |
The present invention relates to the use of a compound of formula I in the manufacture of a medicament for the treatment of schizophrenia, compulsive personality disorder, depression, bipolar disorder, anxiety disorder, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, Cognitive dysfunction, chemotherapy-induced cognitive dysfunction ("chemo brain"), Down's syndrome, autism spectrum disorders, hearing loss, tinnitus, spinal cord cerebral ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke; Radiotherapy, chronic stress, optic neuropathy or macular degeneration; Or a pharmaceutically acceptable acid addition salt, a racemic mixture or a corresponding enantiomer thereof, for the treatment of the neurodegenerative disorder or for the treatment of neurodegenerative disorders or for the abuse of neuroactive drugs such as alcohols, opiates, methamphetamine, phencyclidine or cocaine. And / or the use of optical isomers. In this formula, R 1 is phenyl or pyridinyl optionally substituted with halogen, cyano or halogen-substituted lower alkyl, or is dihydro-pyran-4-yl; R 2 is hydrogen or lower alkyl; R 3 is - (CHR) n -phenyl optionally substituted with lower alkoxy or S (O) 2 -lower alkyl, or heterocycloalkyl optionally substituted with = O and lower alkyl, or is optionally substituted with lower alkyl Substituted lower alkyl, -NR-S (O) 2 -lower alkyl, - (CH 2 ) n -5 or 6-membered heteroaryl, or is hydrogen, lower alkyl, halogen-substituted lower alkyl, (CH 2 ) n -cycloalkyl or - (CH 2 ) n -S (O) 2 -lower alkyl; or R 2 and R 3 are selected from the group consisting of 1,1-dioxo-thiomorpholinyl, morpholinyl, and pyrrolidinyl, optionally substituted with hydroxy, together with the N- atom to which they are attached Form a heterocycloalkyl ring; R is hydrogen or lower alkyl; n is 0, 1 or 2; |